These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32769882)

  • 1. Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.
    Shimizu T; Kawashiri SY; Sato S; Morimoto S; Minoda S; Kawazoe Y; Kuroda S; Tashiro S; Sumiyoshi R; Hosogaya N; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Aug; 99(32):e21480. PubMed ID: 32769882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.
    Kawashiri SY; Shimizu T; Sato S; Morimoto S; Kawazoe Y; Sumiyoshi R; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Jul; 99(30):e21151. PubMed ID: 32791688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of methotrexate in rheumatoid arthritis patients achieving clinical remission by treatment with upadacitinib plus methotrexate (DOPPLER study): A study protocol for an interventional, multicenter, open-label and single-arm clinical trial with clinical, ultrasound and biomarker assessments.
    Shimizu T; Kawashiri SY; Sato S; Kawazoe Y; Kuroda S; Kawasaki R; Ito Y; Morimoto S; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2022 Jan; 101(2):e28463. PubMed ID: 35029189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial.
    Shimizu T; Kawashiri SY; Morimoto S; Kawazoe Y; Kuroda S; Kawasaki R; Ito Y; Kiya R; Sato S; Yamamoto H; Kawakami A
    Trials; 2023 Mar; 24(1):161. PubMed ID: 36869356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.
    Takeuchi T; Nishikawa K; Yamada F; Ohshima S; Inoue M; Yoshioka Y; Yamanaka H
    Mod Rheumatol; 2022 Jul; 32(4):718-727. PubMed ID: 34918129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
    Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR
    Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance.
    Scherlinger M; Germain V; Labadie C; Barnetche T; Truchetet ME; Bannwarth B; Mehsen-Cetre N; Richez C; Schaeverbeke T;
    Joint Bone Spine; 2018 Oct; 85(5):561-567. PubMed ID: 29154920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.
    Takeuchi T; Yamanaka H; Tanaka Y; Sakurai T; Saito K; Ohtsubo H; Lee SJ; Nambu Y
    Mod Rheumatol; 2015; 25(6):817-24. PubMed ID: 25736355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
    Kim TH; Lee SS; Park W; Song YW; Suh CH; Kim S; Lee YN; Yoo DH
    Clin Drug Investig; 2020 Jun; 40(6):541-553. PubMed ID: 32328979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.
    Mazza S; Piazza O Sed N; Conforti FS; Fascì A; Rimondi A; Marinoni B; Casini V; Ricci C; Munari F; Pirola L; Invernizzi P; Girelli C; Lupinacci G; Pastorelli L; Cavallaro F; Ferraris L; Colucci A; Amato A; Eugenio Tontini G; Vecchi M; Fiorino G; Caprioli F
    Clin Transl Sci; 2022 Jan; 15(1):172-181. PubMed ID: 34523800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
    Glintborg B; Sørensen IJ; Loft AG; Lindegaard H; Linauskas A; Hendricks O; Hansen IMJ; Jensen DV; Manilo N; Espesen J; Klarlund M; Grydehøj J; Dieperink SS; Kristensen S; Olsen JS; Nordin H; Chrysidis S; Dalsgaard Pedersen D; Sørensen MV; Andersen LS; Grøn KL; Krogh NS; Pedersen L; Hetland ML;
    Ann Rheum Dis; 2017 Aug; 76(8):1426-1431. PubMed ID: 28473425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis.
    Morita A; Nishikawa K; Yamada F; Yamanaka K; Nakajima H; Ohtsuki M
    J Dermatol; 2022 Oct; 49(10):957-969. PubMed ID: 35799412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
    Codreanu C; Šírová K; Jarošová K; Batalov A
    Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab.
    Tanaka Y; Yamanaka H; Takeuchi T; Inoue M; Saito K; Saeki Y; Lee SJ; Nambu Y
    Mod Rheumatol; 2017 Mar; 27(2):237-245. PubMed ID: 27586879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
    Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W
    Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.
    Sagami S; Nishikawa K; Yamada F; Suzuki Y; Watanabe M; Hibi T
    J Gastroenterol Hepatol; 2021 Aug; 36(8):2091-2100. PubMed ID: 33450057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
    Tweehuysen L; van den Bemt BJF; van Ingen IL; de Jong AJL; van der Laan WH; van den Hoogen FHJ; den Broeder AA
    Arthritis Rheumatol; 2018 Jan; 70(1):60-68. PubMed ID: 29045077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.